Research location
Parçay-les-Pins
France
Advertisement
Research activity in Parçay-les-Pins
FranceCureCurrent currently publishes aggregate city-level research activity for this location: 10 trials and 10 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Parçay-les-Pins
10 linked trials · page 1 of 1Assessment of Comorbidities in Chronic Obstructive Pulmonary Disease (COPD) in European Symptomatic Subjects From Primary CareNCT01516528 · 2011-11-17 · 1 site observation
COMPLETED
Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary DiseaseNCT01126437 · 2010-05-01 · 1 site observation
COMPLETED
Pilot Study With GFT505 (80mg) in Patients Presenting With Impaired Glucose Tolerance and Abdominal Obesity.NCT01275469 · 2009-06-01 · 1 site observation
COMPLETED
Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe HypertensionNCT00926289 · 2009-06-01 · 1 site observation
COMPLETED
Telmisartan 80mg+Hydrochlorothiazide (HCTZ) 25 mg in Hypertension: an Observational StudyNCT00909038 · 2009-05-01 · 1 site observation
COMPLETED
National Survey on HypertensionNCT00804167 · 2008-12-01 · 1 site observation
COMPLETED
Open Label Study Telmisartan and Amlodipine in HypertensionNCT00614380 · 2008-01-01 · 1 site observation
COMPLETED
Telmisartan/Amlodipine (80/5) vs. Telmisartan/Amlodipine (40/5) vs. Amlodipine 10 or 5 in Resistant HypertensionNCT00558428 · 2007-10-01 · 1 site observation
COMPLETED
Acceptability of a Fixed Combination of Fenofibrate and MetforminNCT00348725 · 2005-04-01 · 1 site observation
COMPLETED
A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory ComplaintsNCT00276510 · 2002-02-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.